{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABBV-181", "query": { "intervention": "ABBV-181" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABBV-181&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T19:01:17.316Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06236438", "title": "Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 840, "start_date": "2024-04-10", "completion_date": "2031-10", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-09-08T19:01:17.316Z", "location_count": 19, "location_summary": "La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Winter Haven", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06236438" }, { "nct_id": "NCT03893955", "title": "A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Advanced Solid Tumors", "Triple-Negative Breast Cancer (TNBC)", "Non-small-cell-lung-cancer (NSCLC)", "Metastatic Solid Tumors" ], "interventions": [ { "name": "ABBV-927", "type": "DRUG" }, { "name": "ABBV-368", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2019-05-21", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-08T19:01:17.316Z", "location_count": 13, "location_summary": "Springdale, Arkansas • Santa Rosa, California • New Haven, Connecticut + 10 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Santa Rosa", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03893955" }, { "nct_id": "NCT05599984", "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ABBV-706", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 288, "start_date": "2022-12-05", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-09-08T19:01:17.316Z", "location_count": 22, "location_summary": "Gilbert, Arizona • Duarte, California • Irvine, California + 18 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05599984" }, { "nct_id": "NCT03138408", "title": "SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "SC-004", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 24, "start_date": "2017-06-14", "completion_date": "2019-05-02", "has_results": false, "last_update_posted_date": "2019-05-14", "last_synced_at": "2026-09-08T19:01:17.316Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Duarte, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03138408" }, { "nct_id": "NCT05005403", "title": "Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Micro Satellite Stable Colorectal Cancer", "Gastric/Esophageal Cancer", "High-Grade Serous Ovarian Cancer", "Pancreatic Cancer", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Azirkitug", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Telisotuzumab Adizutecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 694, "start_date": "2021-11-01", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-09-08T19:01:17.316Z", "location_count": 20, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05005403" }, { "nct_id": "NCT03071757", "title": "A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-368", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2017-03-21", "completion_date": "2022-04-13", "has_results": false, "last_update_posted_date": "2022-04-28", "last_synced_at": "2026-09-08T19:01:17.316Z", "location_count": 10, "location_summary": "La Jolla, California • Sacramento, California • Stanford, California + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03071757" }, { "nct_id": "NCT01946074", "title": "A Study of ABT-165 in Subjects With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "ABT-165", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 101, "start_date": "2013-08-08", "completion_date": "2022-09-28", "has_results": false, "last_update_posted_date": "2023-12-15", "last_synced_at": "2026-09-08T19:01:17.316Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01946074" }, { "nct_id": "NCT05822752", "title": "Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Budigalimab", "type": "DRUG" }, { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2023-09-21", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-09-08T19:01:17.316Z", "location_count": 20, "location_summary": "Prescott Valley, Arizona • Springdale, Arkansas • Los Angeles, California + 15 more", "locations": [ { "city": "Prescott Valley", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05822752" }, { "nct_id": "NCT04196283", "title": "A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-368", "type": "DRUG" }, { "name": "Tilsotolimod", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-01-22", "completion_date": "2022-10-27", "has_results": false, "last_update_posted_date": "2023-02-27", "last_synced_at": "2026-09-08T19:01:17.316Z", "location_count": 8, "location_summary": "Chicago, Illinois • Louisville, Kentucky • Detroit, Michigan + 5 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04196283" }, { "nct_id": "NCT03818542", "title": "A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "ABBV-181", "type": "DRUG" }, { "name": "ABBV-368", "type": "DRUG" }, { "name": "ABBV-927", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-01-22", "completion_date": "2020-09-23", "has_results": false, "last_update_posted_date": "2020-12-31", "last_synced_at": "2026-09-08T19:01:17.316Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03818542" } ] }